These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 32356922)

  • 1. Non-alcoholic fatty liver disease is associated with cardiovascular disease in subjects with different glucose tolerance.
    Fiorentino TV; Succurro E; Sciacqua A; Andreozzi F; Perticone F; Sesti G
    Diabetes Metab Res Rev; 2020 Nov; 36(8):e3333. PubMed ID: 32356922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease.
    Nobili V; Mantovani A; Cianfarani S; Alisi A; Mosca A; Sartorelli MR; Maffeis C; Loomba R; Byrne CD; Targher G
    J Hepatol; 2019 Oct; 71(4):802-810. PubMed ID: 31279904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risks of different grades of non-alcoholic fatty liver disease in prediabetic subjects with impaired fasting glucose and glucose tolerance, including the isolated glycosylated hemoglobin levels of 5.7-6.4% in a Chinese population.
    Li CH; Chou YT; Shen WC; Lu FH; Yang YC; Wu JS; Chang CJ
    J Diabetes Investig; 2020 Sep; 11(5):1336-1343. PubMed ID: 32270583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of non-alcoholic fatty liver disease in urban south Indians in relation to different grades of glucose intolerance and metabolic syndrome.
    Mohan V; Farooq S; Deepa M; Ravikumar R; Pitchumoni CS
    Diabetes Res Clin Pract; 2009 Apr; 84(1):84-91. PubMed ID: 19168251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes.
    Targher G; Bertolini L; Padovani R; Rodella S; Zoppini G; Pichiri I; Sorgato C; Zenari L; Bonora E
    J Hepatol; 2010 Oct; 53(4):713-8. PubMed ID: 20619918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose.
    Ou HY; Yang YC; Wu HT; Wu JS; Lu FH; Chang CJ
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4717-23. PubMed ID: 23066121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased prevalence of cardiovascular disease in Type 1 diabetic patients with non-alcoholic fatty liver disease.
    Targher G; Pichiri I; Zoppini G; Trombetta M; Bonora E
    J Endocrinol Invest; 2012 May; 35(5):535-40. PubMed ID: 21795844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi'an, China: a five-year cohort study.
    Ming J; Xu S; Gao B; Liu G; Ji Y; Yang F; Jia Y; Fang Y; Ji Q
    Liver Int; 2015 Nov; 35(11):2401-7. PubMed ID: 25879672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-hour post-load hyperglycemia combined with HbA1c identifies individuals with higher risk of cardiovascular diseases: Cross-sectional data from the CATAMERI study.
    Fiorentino TV; Succurro E; Andreozzi F; Sciacqua A; Perticone F; Sesti G
    Diabetes Metab Res Rev; 2019 Feb; 35(2):e3096. PubMed ID: 30378248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic and alcoholic fatty liver disease - two diseases of affluence associated with the metabolic syndrome and type 2 diabetes: the FIN-D2D survey.
    Kotronen A; Yki-Järvinen H; Männistö S; Saarikoski L; Korpi-Hyövälti E; Oksa H; Saltevo J; Saaristo T; Sundvall J; Tuomilehto J; Peltonen M
    BMC Public Health; 2010 May; 10():237. PubMed ID: 20459722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Risk for Cardiovascular Events in Patients with Diabetic Kidney Disease and Non-Alcoholic Fatty Liver Disease.
    Chinnadurai R; Chrysochou C; Kalra PA
    Nephron; 2019; 141(1):24-30. PubMed ID: 30384370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mean and visit-to-visit variability of glycated hemoglobin, and the risk of non-alcoholic fatty liver disease.
    Yoo JH; Kang M; Kim G; Hur KY; Kim JH; Sinn DH; Jin SM
    J Diabetes Investig; 2021 Jul; 12(7):1252-1262. PubMed ID: 33135331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Morbidity and Comorbidity of Nonalcoholic Fatty Liver Disease and Different Glucose Intolerance Strata in a Community-Based Chinese Population.
    Zhang X; Zhou X; Han X; Fu Z; Wang L; Li Y; Ji L
    Metab Syndr Relat Disord; 2020 Aug; 18(6):284-290. PubMed ID: 32460629
    [No Abstract]   [Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease is associated with a decreased myocardial mechano-energetic efficiency.
    Fiorentino TV; Miceli S; Succurro E; Sciacqua A; Andreozzi F; Sesti G
    J Intern Med; 2021 Feb; 289(2):221-231. PubMed ID: 32633873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease (NAFLD) and 10-year risk of cardiovascular diseases.
    Motamed N; Rabiee B; Poustchi H; Dehestani B; Hemasi GR; Khonsari MR; Maadi M; Saeedian FS; Zamani F
    Clin Res Hepatol Gastroenterol; 2017 Feb; 41(1):31-38. PubMed ID: 27597641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes.
    Li M; Zhao Z; Qin G; Chen L; Lu J; Huo Y; Chen L; Zeng T; Xu M; Chen Y; Wang T; Wang S; Xu Y; Shi L; Tang X; Su Q; Yu X; Yan L; Wan Q; Chen G; Gao Z; Wang G; Shen F; Luo Z; Zhang Y; Liu C; Wang Y; Hu R; Ye Z; Wu S; Deng H; Yang T; Li Q; Qin Y; Mu Y; Zhao J; Ning G; Bi Y; Xu Y; Wang W
    Metabolism; 2021 Nov; 124():154874. PubMed ID: 34517014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in glucose intolerance status and risk of incident cardiovascular disease: Tehran Lipid and Glucose Study.
    Kabootari M; Hasheminia M; Azizi F; Mirbolouk M; Hadaegh F
    Cardiovasc Diabetol; 2020 Mar; 19(1):41. PubMed ID: 32228577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coffee consumption is not associated with prevalent subclinical cardiovascular disease (CVD) or the risk of CVD events, in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis.
    Simon TG; Trejo MEP; Zeb I; Frazier-Wood AC; McClelland RL; Chung RT; Budoff MJ
    Metabolism; 2017 Oct; 75():1-5. PubMed ID: 28964324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease.
    Morio R; Hyogo H; Hatooka M; Morio K; Kan H; Kobayashi T; Kawaoka T; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Aikata H; Ochi H; Masayasu Y; Chayama K
    J Gastroenterol; 2017 Feb; 52(2):253-262. PubMed ID: 27351871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.